Compare CGTX & RGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CGTX | RGS |
|---|---|---|
| Founded | 2007 | 1922 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.6M | 72.7M |
| IPO Year | 2021 | 1994 |
| Metric | CGTX | RGS |
|---|---|---|
| Price | $1.02 | $27.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $3.33 | N/A |
| AVG Volume (30 Days) | ★ 524.4K | 5.0K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.79 | 20.24 |
| EPS | N/A | ★ 0.89 |
| Revenue | N/A | ★ $210,134,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $31.16 |
| Revenue Growth | N/A | ★ 3.52 |
| 52 Week Low | $0.55 | $18.76 |
| 52 Week High | $3.83 | $31.50 |
| Indicator | CGTX | RGS |
|---|---|---|
| Relative Strength Index (RSI) | 49.44 | 51.82 |
| Support Level | $1.02 | $25.96 |
| Resistance Level | $1.18 | $28.44 |
| Average True Range (ATR) | 0.06 | 1.08 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 52.52 | 59.49 |
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
Regis Corporation owns, franchises, and operates beauty salons in North America and the U.K., serving mainly price-conscious customers. Its salons, located mostly in strip malls, shopping centers, and Walmart stores, offer services like haircutting, styling, shampooing, conditioning, and hair coloring, along with hair care and beauty products. The company's primary brands include Supercuts, SmartStyle, and Cost Cutters. Regis generates the majority of its revenue from these mass-market locations and reports operations in two segments: franchise and company-owned, with services making up about 94% of company-owned salon sales.